CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.28M, lower than 95% of all stocks globally
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
2.43MGBP3.28M · vs all stocks (USD)
Revenue (TTM)
1.70MGBP2.29M · vs all stocks (USD)
Beta
0.0210xvs all stocks
52-Week Change
-96.66%vs all stocks
Market Capitalization
2.43MGBP3.28M · vs all stocks (USD)
Enterprise Value
-971.68KGBP-1.31M · vs all stocks (USD)
Forward P/E
-0.5603xvs Biotechnology peers
Price to Sales (TTM)
1.43xvs Biotechnology peers
Price to Book (MRQ)
0.8360xvs Biotechnology peers
Enterprise to Revenue
-0.5730xvs Biotechnology peers
Enterprise to EBITDA
0.1080xvs Biotechnology peers
Operating Margin
-342.88%vs Biotechnology peers
Return on Assets (TTM)
-60.54%vs Biotechnology peers
Return on Equity (TTM)
-154.16%vs Biotechnology peers
Revenue (TTM)
1.70MGBP2.29M · vs all stocks (USD)
Revenue per Share (TTM)
0.0050GBPUpdated Aug 1, 2026Quarterly Revenue Growth
-90.00%vs Biotechnology peers
Gross Profit (TTM)
1.24MGBP1.67M · vs all stocks (USD)
EBITDA (TTM)
-8.99MGBP-12.14M · vs all stocks (USD)
Net Income (TTM)
-9.07MGBP-12.25M · vs all stocks (USD)
Operating Cash Flow (TTM)
-5.62MGBP-7.58M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-4.88MGBP-6.59M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 1, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
13.93MGBPFY2024 · Dec 31, 2024Cost of Goods Sold
4.24MGBPFY2024 · Dec 31, 2024Gross Profit
9.69MGBPFY2024 · Dec 31, 2024Operating Income
1.24MGBP1.68M · vs all stocks (USD)
Pre-tax Income
1.29MGBPFY2024 · Dec 31, 2024Income Tax Expense
-2.17KGBPFY2024 · Dec 31, 2024Net Income
1.29MGBPFY2024 · Dec 31, 2024EBIT
1.24MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
1.37MGBPFY2024 · Dec 31, 2024Research & Development
1.74MGBPFY2024 · Dec 31, 2024Selling, General & Administrative
6.83MGBPFY2024 · Dec 31, 2024Non-operating Interest Income
46.94KGBPFY2024 · Dec 31, 2024EPS (Basic)
0.0043GBPFY2024 · Dec 31, 2024EPS (Diluted)
0.0041GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
302.12MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
302.12MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
1.29MGBPFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
1.60MGBPFY2024 · Dec 31, 2024Free Cash Flow
-124.83KGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
6.60MGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
1.29MGBPFY2024 · Dec 31, 2024Stock-based Compensation
2.02MGBPFY2024 · Dec 31, 2024Other Non-cash Items
-46.94KGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-1.21MGBPFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-455.57KGBPFY2024 · Dec 31, 2024Capital Expenditures
-1.73MGBPFY2024 · Dec 31, 2024Net Investing Cash Flow
-1.73MGBPFY2024 · Dec 31, 2024Net Financing Cash Flow
170.91KGBPFY2024 · Dec 31, 2024Shares Outstanding
581.33MSharesUpdated Aug 1, 2026Float Shares
526.03MSharesUpdated Aug 1, 2026% Held by Insiders
12.84%vs all stocks
% Held by Institutions
11.85%vs all stocks
Total Cash (MRQ)
3.40MGBP4.59M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0060GBPUpdated Aug 1, 2026Total Debt (MRQ)
0.00GBPvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
2.06xvs Biotechnology peers
Book Value per Share (MRQ)
0.0050GBPUpdated Aug 1, 2026Total Assets
13.59MGBP18.35M · vs all stocks (USD)
Total Current Assets
9.50MGBPFY2024 · Dec 31, 2024Total Liabilities
4.63MGBPFY2024 · Dec 31, 2024Total Non-current Assets
4.09MGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
782.59KGBPFY2024 · Dec 31, 2024Total Current Liabilities
3.84MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
6.60MGBPFY2024 · Dec 31, 2024Accounts Receivable
1.27MGBPFY2024 · Dec 31, 2024Inventory
455.91KGBPFY2024 · Dec 31, 2024Accounts Payable
1.49MGBPFY2024 · Dec 31, 2024Common Stock (Book)
607.41KGBPFY2024 · Dec 31, 2024Retained Earnings
-64.03MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
8.96MGBP12.10M · vs all stocks (USD)
52-Week Low
0.2440GBXUpdated Aug 1, 202652-Week High
12.58GBXUpdated Aug 1, 202652-Week Change
-96.66%vs all stocks
Beta
0.0210xvs all stocks
50-Day MA
0.5173GBXUpdated Aug 1, 2026200-Day MA
1.10GBXUpdated Aug 1, 2026Avg 10-Day Volume
2.07MSharesUpdated Aug 1, 2026Avg 30-Day Volume
7.28MSharesUpdated Aug 1, 2026Diluted EPS (TTM)
-0.0300GBPUpdated Aug 1, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
SBC-to-Net-Income Elevated, SBC-to-Revenue Elevated, And Diluted Share Count Growing (6Y CAGR)
Pay in shares is large next to its revenue and its profit, and the share count keeps rising.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.28M, lower than 95% of all stocks globallySignificant
Market cap (USD): 3,281,720.468Global P5: 269,387,740.27
Revenue is $2.29M, lower than 95% of all stocks globallySignificant
Revenue (USD): 2,291,390.23Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Nuformix Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Roquefort Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
TheracryF PLC
Tier 1ProductionApproval-Gated PipelineRule
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
XTL Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Defi Technologies Inc.
3 interpretationsSBC-to-Net-Income Elevated, SBC-to-Revenue Elevated, And Diluted Share Count Growing (6Y CAGR)Decline With Range Expansion And DrawdownMinimal Tax and Interest Drag
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownMinimal Tax and Interest Drag
Zhejiang Hangke Technology Co., Ltd.
2 interpretationsDecline With Range Expansion And DrawdownMinimal Tax and Interest Drag